http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 강원택(Won Tak Kang) (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
혈액투석 환자의 신성 빈혈에 대한 Recombinant Huyman Erythropoietin 의 효과
강원택(Won Tak Kang),서재석(Jae Suk Suh),황금만(Keum Man Hwang),박창현(Chang Hyun Park),박성광(Sung Kwang Park),강성귀(Sung Kyew Kang) 대한내과학회 1992 대한내과학회지 Vol.43 No.3
Anemia is a major and predictable complication of chronic renal failure. When end-stage renal failure evolves, the anemia is frequently severe and often impairs rehabilitation despite adequate dialysis therapy. Now we administered recombinant human erythropaietin (rhuEPO) to 8nemic patients with end-stage renal failure who were undergoing hemodialysis. The recombinant human erythropoietin was given intravenously three or two times a week after dialysis. Transfusion requirements, hematocrit, ferrokinetics and adverse reactions were monitored. In 8patients treated for 16weeks, hemoglobin increased from initial mean (±SD) 6.86±0.68g/di to 9.36±0.87g/dl (p<0.01). Hematocrit increased from initial mean 19.4±2.1% to 28.0±2.6(p<0.01). Serum iron decreased from initial mean 202.6±77.9㎍/dl to 67.4±20.2㎍/dl (p<0.01) and ferritin decreased but it was not significant stastically (p>0.05). Uric acid increased from initial mean 6.5±1.1mg/dl to 8.3±0.9mg/dl (p<0.05). Adverse reactions was one hypertension acceleration and chest pain, but was no vascular access thrombosis. These results suggest that Recombinant Human Erythropoietin is effective and may be eliminate the need for transfusion with their risks of immunologic sensitization, infection and iron overload and can restore the hematocrit to normal in anemic patients of end-stage renal failure.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
